Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.

Oldenhuis CN, Loos WJ, Esteves B, van Doorn L, Cotreau MM, Strahs AL, den Hollander MW, Gietema JA, de Vries EG, Eskens FA.

Clin Colorectal Cancer. 2015 Mar;14(1):18-24.e1. doi: 10.1016/j.clcc.2014.12.001. Epub 2014 Dec 16.

PMID:
25591799
2.

The issue of non-specific binding of cabazitaxel.

de Bruijn P, Moghaddam-Helmantel IM, Loos WJ, Mathijssen RH, Wiemer EA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Aug 1;932:74-5. doi: 10.1016/j.jchromb.2013.06.016. Epub 2013 Jun 17. No abstract available.

PMID:
23831699
3.

Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography.

van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, Comans EF, Rutten HB, Eriksson J, Windhorst AD, Hendrikse NH, Postmus PE, Smit EF, Lammertsma AA.

Clin Cancer Res. 2013 Aug 1;19(15):4163-73. doi: 10.1158/1078-0432.CCR-12-3779. Epub 2013 Apr 25.

4.

A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.

Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WT, Friberg LE, Schiavon G, Wiemer EA, Verweij J, Loos WJ, Mathijssen RH, De Giorgi U.

Clin Cancer Res. 2012 Oct 15;18(20):5780-7. doi: 10.1158/1078-0432.CCR-12-0490. Epub 2012 Jul 31.

5.

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A.

Clin Cancer Res. 2012 Aug 15;18(16):4433-40. Epub 2012 Jun 18.

6.

Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.

de Graan AJ, Loos WJ, Friberg LE, Baker SD, van der Bol JM, van Doorn L, Wiemer EA, van der Holt B, Verweij J, Mathijssen RH.

Clin Cancer Res. 2012 Aug 15;18(16):4425-32. doi: 10.1158/1078-0432.CCR-12-0728. Epub 2012 May 29.

7.

Effects of CYP induction by rifampicin on tamoxifen exposure.

Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RH, Verweij J, Mathijssen RH.

Clin Pharmacol Ther. 2012 Jul;92(1):62-7. doi: 10.1038/clpt.2011.372. Epub 2012 May 23.

PMID:
22617226
8.

Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.

Sprowl JA, Gregorc V, Lazzari C, Mathijssen RH, Loos WJ, Sparreboom A.

Clin Pharmacol Ther. 2012 Jun;91(6):1022-6. doi: 10.1038/clpt.2011.330.

9.

Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.

de Bruijn P, de Graan AJ, Nieuweboer A, Mathijssen RH, Lam MH, de Wit R, Wiemer EA, Loos WJ.

J Pharm Biomed Anal. 2012 Feb 5;59:117-22. doi: 10.1016/j.jpba.2011.10.010. Epub 2011 Oct 24.

PMID:
22079047
10.

Determining the best dose for the individual patient.

Mathijssen RH, Loos WJ, Verweij J.

J Clin Oncol. 2011 Nov 20;29(33):4345-6. doi: 10.1200/JCO.2011.38.2572. Epub 2011 Oct 17. No abstract available.

PMID:
22010022
11.

Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.

Binkhorst L, Mathijssen RH, Ghobadi Moghaddam-Helmantel IM, de Bruijn P, van Gelder T, Wiemer EA, Loos WJ.

J Pharm Biomed Anal. 2011 Dec 15;56(5):1016-23. doi: 10.1016/j.jpba.2011.08.002. Epub 2011 Aug 5.

PMID:
21872414
12.

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt B, Verweij J, Seynaeve C, Beijnen JH, Mathijssen RH.

J Clin Oncol. 2011 Aug 20;29(24):3240-6. doi: 10.1200/JCO.2010.32.9839. Epub 2011 Jul 18.

PMID:
21768449
13.

Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.

Schiavon G, Eechoute K, Mathijssen RH, de Bruijn P, van der Bol JM, Verweij J, Sleijfer S, Loos WJ.

J Clin Pharmacol. 2012 Jul;52(7):1115-20. doi: 10.1177/0091270011409235. Epub 2011 May 20. No abstract available.

PMID:
21602518
14.

Environmental and genetic factors affecting transport of imatinib by OATP1A2.

Eechoute K, Franke RM, Loos WJ, Scherkenbach LA, Boere I, Verweij J, Gurney H, Kim RB, Tirona RG, Mathijssen RH, Sparreboom A.

Clin Pharmacol Ther. 2011 Jun;89(6):816-20. doi: 10.1038/clpt.2011.42. Epub 2011 Apr 20.

15.

Drug transporters of platinum-based anticancer agents and their clinical significance.

Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA.

Drug Resist Updat. 2011 Feb;14(1):22-34. doi: 10.1016/j.drup.2010.12.002. Epub 2011 Jan 20. Review.

PMID:
21251871
16.

Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study.

Engels FK, Loos WJ, van der Bol JM, de Bruijn P, Mathijssen RH, Verweij J, Mathot RA.

Clin Cancer Res. 2011 Jan 15;17(2):353-62. doi: 10.1158/1078-0432.CCR-10-1636. Epub 2011 Jan 11.

17.

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.

van der Bol JM, Loos WJ, de Jong FA, van Meerten E, Konings IR, Lam MH, de Bruijn P, Wiemer EA, Verweij J, Mathijssen RH.

Eur J Cancer. 2011 Apr;47(6):831-8. doi: 10.1016/j.ejca.2010.11.030. Epub 2011 Jan 6.

18.

Drug transporters and imatinib treatment: implications for clinical practice.

Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH.

Clin Cancer Res. 2011 Feb 1;17(3):406-15. doi: 10.1158/1078-0432.CCR-10-2250. Epub 2010 Dec 16. Review.

19.

Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.

Loos WJ, de Graan AJ, de Bruijn P, van Schaik RH, van Fessem MA, Lam MH, Mathijssen RH, Wiemer EA.

J Pharm Biomed Anal. 2011 Jan 25;54(2):387-94. doi: 10.1016/j.jpba.2010.08.033. Epub 2010 Sep 21.

PMID:
20926215
20.

Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.

Lancaster CS, Hu C, Franke RM, Filipski KK, Orwick SJ, Chen Z, Zuo Z, Loos WJ, Sparreboom A.

Clin Cancer Res. 2010 Oct 1;16(19):4789-99. doi: 10.1158/1078-0432.CCR-10-1239. Epub 2010 Sep 21.

21.

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.

de Jonge MJ, Slingerland M, Loos WJ, Wiemer EA, Burger H, Mathijssen RH, Kroep JR, den Hollander MA, van der Biessen D, Lam MH, Verweij J, Gelderblom H.

Eur J Cancer. 2010 Nov;46(16):3016-21. doi: 10.1016/j.ejca.2010.07.015. Epub 2010 Aug 26.

PMID:
20801016
22.

Effects of methimazole on the elimination of irinotecan.

van der Bol JM, Visser TJ, Loos WJ, de Jong FA, Wiemer EA, van Aken MO, Planting AS, Schellens JH, Verweij J, Mathijssen RH.

Cancer Chemother Pharmacol. 2011 Jan;67(1):231-6. doi: 10.1007/s00280-010-1414-x. Epub 2010 Aug 1.

23.

Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.

Konings IR, Sleijfer S, Mathijssen RH, de Bruijn P, Ghobadi Moghaddam-Helmantel IM, van Dam LM, Wiemer EA, Verweij J, Loos WJ.

Cancer Chemother Pharmacol. 2011 May;67(5):1055-62. doi: 10.1007/s00280-010-1400-3. Epub 2010 Jul 23.

24.

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.

Hamberg P, Steeghs N, Loos WJ, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S.

Br J Cancer. 2010 Jun 8;102(12):1699-706. doi: 10.1038/sj.bjc.6605696. Epub 2010 May 18.

25.

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

van der Bol JM, Mathijssen RH, Creemers GJ, Planting AS, Loos WJ, Wiemer EA, Friberg LE, Verweij J, Sparreboom A, de Jong FA.

Clin Cancer Res. 2010 Jan 15;16(2):736-42. doi: 10.1158/1078-0432.CCR-09-1526. Epub 2010 Jan 12.

26.

Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).

Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA.

Br J Pharmacol. 2010 Feb;159(4):898-908. doi: 10.1111/j.1476-5381.2009.00569.x. Epub 2010 Jan 8.

27.

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.

de Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ.

J Pharm Biomed Anal. 2010 Mar 11;51(4):934-41. doi: 10.1016/j.jpba.2009.10.020. Epub 2009 Oct 31.

PMID:
19931354
28.

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S.

Clin Cancer Res. 2009 Sep 1;15(17):5584-90. doi: 10.1158/1078-0432.CCR-09-0996. Epub 2009 Aug 18. Erratum in: Clin Cancer Res. 2009 Nov 1;15(21):6744.

29.

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.

de Bruijn P, Moghaddam-Helmantel IM, de Jonge MJ, Meyer T, Lam MH, Verweij J, Wiemer EA, Loos WJ.

J Pharm Biomed Anal. 2009 Dec 5;50(5):977-82. doi: 10.1016/j.jpba.2009.06.048. Epub 2009 Jul 7.

PMID:
19628352
30.

Application of prolonged microdialysis sampling in carboplatin-treated cancer patients.

Konings IR, Engels FK, Sleijfer S, Verweij J, Wiemer EA, Loos WJ.

Cancer Chemother Pharmacol. 2009 Aug;64(3):509-16. doi: 10.1007/s00280-008-0898-0. Epub 2008 Dec 20.

31.

The relevance of microdialysis for clinical on:cology.

Kitzen JJ, Verweij J, Wiemer EA, Loos WJ.

Curr Clin Pharmacol. 2006 Sep;1(3):255-63. Review.

PMID:
18666750
32.

Interaction of Cisplatin with the human organic cation transporter 2.

Filipski KK, Loos WJ, Verweij J, Sparreboom A.

Clin Cancer Res. 2008 Jun 15;14(12):3875-80. doi: 10.1158/1078-0432.CCR-07-4793.

33.

Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation.

Lugtenberg RT, Cransberg K, Loos WJ, Wagner A, Alders M, van den Heuvel-Eibrink MM.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1039-44. doi: 10.1007/s00280-008-0694-x. Epub 2008 Feb 14.

PMID:
18273617
34.

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.

Heijns JB, van der Burg ME, van Gelder T, Fieren MW, de Bruijn P, van der Gaast A, Loos WJ.

Cancer Chemother Pharmacol. 2008 Oct;62(5):841-7. doi: 10.1007/s00280-007-0671-9. Epub 2008 Jan 19.

35.

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.

Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S.

Oncologist. 2007 Nov;12(11):1351-60. Review.

36.

Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.

de Jong FA, van der Bol JM, Mathijssen RH, Loos WJ, Mathôt RA, Kitzen JJ, van den Bent MJ, Verweij J.

Cancer Biol Ther. 2007 Sep;6(9):1368-74. Epub 2007 Jun 13.

PMID:
17873515
37.

Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.

Loos WJ, Zamboni WC, Engels FK, de Bruijn P, Lam MH, de Wit R, Verweij J, Wiemer EA.

J Pharm Biomed Anal. 2007 Oct 18;45(2):288-94. Epub 2007 Jul 26.

PMID:
17804188
38.

Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A.

Oncologist. 2007 Aug;12(8):913-23.

39.

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de Jong FA.

J Clin Oncol. 2007 Jul 1;25(19):2719-26. Epub 2007 Jun 11.

PMID:
17563393
40.

Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

Engels FK, de Jong FA, Sparreboom A, Mathot RA, Loos WJ, Kitzen JJ, de Bruijn P, Verweij J, Mathijssen RH.

Oncologist. 2007 Mar;12(3):291-300.

41.

Influence of ketoconazole on the fecal and urinary disposition of docetaxel.

Engels FK, Loos WJ, Mathot RA, van Schaik RH, Verweij J.

Cancer Chemother Pharmacol. 2007 Sep;60(4):569-79. Epub 2007 Jan 26.

PMID:
17256132
42.

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.

Loos WJ, de Wit R, Freedman SJ, Van Dyck K, Gambale JJ, Li S, Murphy GM, van Noort C, de Bruijn P, Verweij J.

Cancer Chemother Pharmacol. 2007 Feb;59(3):407-12. Epub 2006 Oct 19.

PMID:
17051369
43.

Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.

de Jong FA, Kitzen JJ, de Bruijn P, Verweij J, Loos WJ.

Cancer Biol Ther. 2006 Sep;5(9):1105-10. Epub 2006 Sep 19.

PMID:
16969123
44.

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.

Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J.

Cancer Biol Ther. 2006 Jul;5(7):833-9. Epub 2006 Jul 22.

PMID:
16775418
45.

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.

Gietema JA, Hoekstra R, de Vos FY, Uges DR, van der Gaast A, Groen HJ, Loos WJ, Knight RA, Carr RA, Humerickhouse RA, Eskens FA.

Ann Oncol. 2006 Aug;17(8):1320-7. Epub 2006 May 25.

46.

Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

Loos WJ, de Jongh FE, Sparreboom A, de Wit R, van Boven-van Zomeren DM, Stoter G, Nooter K, Verweij J.

J Clin Oncol. 2006 Apr 1;24(10):1499-506.

PMID:
16574999
47.

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.

Felici A, Loos WJ, Verweij J, Cirillo I, de Bruijn P, Nooter K, Mathijssen RH, de Jonge MJ.

Cancer Chemother Pharmacol. 2006 Nov;58(5):673-80. Epub 2006 Mar 17.

PMID:
16544143
48.

Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method.

Engels FK, Buijs D, Loos WJ, Verweij J, Bakker WH, Krenning EP.

Anticancer Drugs. 2006 Jan;17(1):63-7.

PMID:
16317291
49.

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.

Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Viganò L, Locatelli A, Verweij J, Sparreboom A, McLeod HL.

Clin Cancer Res. 2005 Nov 15;11(22):8097-104.

50.

Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).

Scripture CD, Szebeni J, Loos WJ, Figg WD, Sparreboom A.

Cancer Biol Ther. 2005 May;4(5):555-60. Epub 2005 May 10.

PMID:
15917657

Supplemental Content

Support Center